Maxigen Biotech Inc - Asset Resilience Ratio
Maxigen Biotech Inc (1783) has an Asset Resilience Ratio of 15.14% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Maxigen Biotech Inc's Asset Resilience Ratio has changed over time. Check Maxigen Biotech Inc (1783) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Maxigen Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Maxigen Biotech Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$301.50 Million | 15.14% |
| Total Liquid Assets | NT$301.50 Million | 15.14% |
Asset Resilience Insights
- Good Liquidity Position: Maxigen Biotech Inc maintains a healthy 15.14% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Maxigen Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Maxigen Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.46% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Annual Asset Resilience Ratio for Maxigen Biotech Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Maxigen Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.93% | NT$301.50 Million ≈ $9.50 Million |
NT$1.89 Billion ≈ $59.64 Million |
+15.83pp |
| 2024-12-31 | 0.09% | NT$1.50 Million ≈ $47.26K |
NT$1.58 Billion ≈ $49.86 Million |
-0.01pp |
| 2023-12-31 | 0.10% | NT$1.50 Million ≈ $47.26K |
NT$1.49 Billion ≈ $47.04 Million |
-0.61pp |
| 2022-12-31 | 0.71% | NT$10.32 Million ≈ $325.01K |
NT$1.45 Billion ≈ $45.61 Million |
-1.41pp |
| 2021-12-31 | 2.12% | NT$26.87 Million ≈ $846.62K |
NT$1.27 Billion ≈ $39.86 Million |
+0.75pp |
| 2020-12-31 | 1.37% | NT$13.13 Million ≈ $413.82K |
NT$956.47 Million ≈ $30.13 Million |
-12.55pp |
| 2019-12-31 | 13.92% | NT$165.05 Million ≈ $5.20 Million |
NT$1.19 Billion ≈ $37.35 Million |
-6.53pp |
| 2018-12-31 | 20.45% | NT$232.25 Million ≈ $7.32 Million |
NT$1.14 Billion ≈ $35.77 Million |
+9.31pp |
| 2017-12-31 | 11.15% | NT$123.05 Million ≈ $3.88 Million |
NT$1.10 Billion ≈ $34.78 Million |
-12.37pp |
| 2016-12-31 | 23.52% | NT$258.07 Million ≈ $8.13 Million |
NT$1.10 Billion ≈ $34.57 Million |
+4.13pp |
| 2015-12-31 | 19.39% | NT$226.53 Million ≈ $7.14 Million |
NT$1.17 Billion ≈ $36.81 Million |
-23.56pp |
| 2014-12-31 | 42.95% | NT$435.41 Million ≈ $13.72 Million |
NT$1.01 Billion ≈ $31.94 Million |
+11.95pp |
| 2013-12-31 | 31.00% | NT$314.50 Million ≈ $9.91 Million |
NT$1.01 Billion ≈ $31.96 Million |
+23.83pp |
| 2012-12-31 | 7.17% | NT$36.26 Million ≈ $1.14 Million |
NT$505.76 Million ≈ $15.93 Million |
-4.97pp |
| 2011-12-31 | 12.14% | NT$59.09 Million ≈ $1.86 Million |
NT$486.65 Million ≈ $15.33 Million |
+11.95pp |
| 2010-12-31 | 0.19% | NT$820.00K ≈ $25.83K |
NT$429.76 Million ≈ $13.54 Million |
-0.93pp |
| 2009-12-31 | 1.12% | NT$3.85 Million ≈ $121.36K |
NT$343.55 Million ≈ $10.82 Million |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more